Related Experiment Video
Updated: Jun 22, 2026
Discrimination and Characterization of Heterocellular Populations Using Quantitative Imaging Techniques
Published on: June 30, 2017
Assessment of erlotinib in chemoresponse assay
Shara D Rice1, Jason E Bush, Stacey L Brower
1Precision Therapeutics, Inc., Pittsburgh, PA 15203, U.S.A.
Background:
There is a need to identify the subset of patients sensitive to epidermal growth factor receptor (EGFR) inhibition prior to using such treatments.
Materials And Methods:
Three non-small cell lung cancer (NSCLC) cell lines (H292, H358, and Calu3) and 34 primary human lung tumor specimens were tested for chemoresponse to erlotinib.
Results:
The assay distinguished responsiveness to erlotinib among NSCLC cell lines and human lung tumor explants. The H292 cells were responsive, the Calu3 cells were intermediate responsive and the H358 cells were non-responsive. These results were consistent with published tumor growth inhibition by erlotinib in xenografts derived from these cell lines. Out of the 34 patient specimens, 3 (8.8%) were responsive to erlotinib, 7 (20.6%) were intermediate responsive and 24 (70.6%) were non-responsive.
Conclusion:
The in vitro chemoresponse assay profile was similar to that noted for human tumors in clinical trials. Chemoresponse testing may help predict patient response to erlotinib and assist chemotherapy decision-making.
Insights
An in vitro assay can predict patient response to erlotinib, a treatment for non-small cell lung cancer (NSCLC). This chemoresponse testing helps identify sensitive patients, aiding chemotherapy decisions.
Area of Science:
- Oncology
- Pharmacology
Background:
- Identifying patients sensitive to epidermal growth factor receptor (EGFR) inhibitors is crucial for effective lung cancer treatment.
- Erlotinib is an EGFR inhibitor used in non-small cell lung cancer (NSCLC) therapy.
Purpose of the Study:
- To evaluate an in vitro chemoresponse assay for predicting patient response to erlotinib in NSCLC.
- To determine the feasibility of using chemoresponse testing to guide erlotinib treatment decisions.
Main Methods:
- Tested erlotinib chemoresponse in three NSCLC cell lines (H292, H358, Calu3).
- Assessed erlotinib chemoresponse in 34 primary human lung tumor specimens.
- Correlated in vitro assay results with known erlotinib efficacy.
Main Results:
- The assay differentiated erlotinib responsiveness in NSCLC cell lines: H292 (responsive), Calu3 (intermediate), H358 (non-responsive).
- In patient specimens, 8.8% were responsive, 20.6% intermediate, and 70.6% non-responsive to erlotinib.
- In vitro results aligned with published xenograft data and clinical trial observations.
Conclusions:
- The in vitro chemoresponse assay accurately reflects erlotinib sensitivity observed in clinical settings.
- Chemoresponse testing shows potential for predicting patient response to erlotinib.
- This assay may assist in personalized chemotherapy decision-making for NSCLC patients.